Search Medical Condition
Please enter condition
Please choose location from dropdown

Yamato-shi, Kanagawa, Japan Clinical Trials

A listing of Yamato-shi, Kanagawa, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (196) clinical trials

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone. The study will last approximately 47 weeks and may include about 15 visits.

Phase

0.28 miles

Learn More »

A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

The purpose of this study is to determine the long-term safety of the study drug tirzepatide in combination with oral antihyperglycemic medications in participants with type 2 diabetes.

Phase

0.28 miles

Learn More »

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

Phase

2.69 miles

Learn More »

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

A multi-regional clinical trial with participating sites planned in the following countries pending approval from the applicable oversight authorities: Argentina Brazil Bulgaria Canada Colombia Czech Republic Denmark France Germany Hungary India Israel Japan Mexico Netherlands Poland Romania Russian Federation Slovakia South Africa Spain Ukraine United Kingdom United States

Phase

2.69 miles

Learn More »

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

This study will examine the long-term safety and efficacy of rIX-FP for the control and prevention of bleeding episodes in children and adults with severe hemophilia B. The study will include subjects who have not previously been treated with Factor IX products, subjects who previously completed a CSL-sponsored rIX-FP lead-in ...

Phase

2.78 miles

Learn More »

ADYNOVATE Drug Use-Results Survey

The purpose of this survey is to understand the following items in the actual clinical use of ADYNOVATE in patients: Unexpected adverse drug reactions Occurrence of adverse drug reactions in the actual clinical use Factors that may affect safety and efficacy Occurrence of Factor VIII inhibitor development in patients with ...

Phase N/A

2.78 miles

Learn More »

Heart Failure and Sudden Cardiac Death Japan Registry

The purpose of this observational registry is to collect clinical events and outcome data in 4 different study populations (cohorts), with a majority of Japanese subjects, that are at risk of sudden cardiac death (SCD) and heart failure (HF) events. These event rates will be compared with available published data ...

Phase N/A

2.78 miles

Learn More »

The Efficacy of Therapy Focused on Desire-satisfaction for Disordered Gamblers

Introduction Gambling disorder is a public health problem characterized by persistent and recurrent maladaptive patterns of gambling. A prevalence rate was 0.4-2.0% worldwide. In Japan, gambling is common: the prevalence rate of disordered gamblers is estimated to be 5.5% of adults.Gambling disorder resulted in clinical and subclinical harms, which are ...

Phase N/A

3.49 miles

Learn More »

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.

Phase

3.54 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in patients with manifest Huntington's disease (HD).

Phase

3.54 miles

Learn More »